146 related articles for article (PubMed ID: 2212836)
1. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer].
Anzai K; Kurihara M; Izumi T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study of the NCC-ST-439 EIA kit using serum from patients with various types of cancer and benign disease (2)].
Ohkura H; Hattori N; Miyazaki I; Sawabu N; Tobe R; Kawai K; Abe O; Ishii M; Kawai T; Kamano T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1907-12. PubMed ID: 2439021
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of serum NCC-ST 439 as a tumor marker for colorectal cancer].
Yamaguchi A; Kurosaka Y; Ohta N; Kamata T; Ishida T; Nishimura G; Katoh M; Kosaka T; Yonemura Y; Miyazaki I
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2645-50. PubMed ID: 2549882
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of serum level of NCC-ST-439 as a new tumor marker for colorectal diseases--fluctuation of serum NCC-ST-439 in patients with colorectal cancers before and after surgery].
Sakurai Y; Kodaira S; Teramoto T; Sugano K; Abe O; Ohtake H; Iri H
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3205-12. PubMed ID: 2782914
[TBL] [Abstract][Full Text] [Related]
5. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
[TBL] [Abstract][Full Text] [Related]
6. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemical study of cancer-associated carbohydrate antigens in carcinoma of the biliary tract].
Sasaki R
Nihon Geka Gakkai Zasshi; 1989 Dec; 90(12):1976-88. PubMed ID: 2560529
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
Iemura K; Moriya Y
Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
[TBL] [Abstract][Full Text] [Related]
11. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of the NCC-ST-439 EIA kit using serum from patients with various types of cancer and benign disease (1)].
Ohkura H; Hattori N; Miyazaki I; Sawabu N; Tobe R; Kawai K; Abe O; Ishii M; Kawai T; Kamano T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1901-6. PubMed ID: 2439020
[TBL] [Abstract][Full Text] [Related]
13. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
Matsuda M; Shimizu Y; Chikamatsu E; Takayanagi K; Ishigure H; Murakami S; Odani K
Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of non-invasive diagnostic tests in detecting cancer of the pancreas.
Wang JY; Chen FZ; Yang YZ
Chin Med J (Engl); 1990 Oct; 103(10):817-20. PubMed ID: 2125254
[TBL] [Abstract][Full Text] [Related]
15. [Tumor markers--personal experience. The use of tumor markers for cancer of digestive organs].
Ishii M
Gan To Kagaku Ryoho; 1991 May; 18(6):1059-65. PubMed ID: 1709347
[TBL] [Abstract][Full Text] [Related]
16. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Huang C; Bei L; Liu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of serum TAC-41 in various digestive cancers].
Sato S; Yamanaka T; Kimura K
Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer].
Koizumi F; Odagiri H; Fujimoto H; Kawamura T; Ishimori A
Rinsho Byori; 1992 May; 40(5):523-8. PubMed ID: 1507478
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen].
Olsson NO; Crimet-Montange D; Martin F
Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449
[TBL] [Abstract][Full Text] [Related]
20. [Monoclonal antibodies. Their usefulness in the diagnosis of malignant tumors of the digestive system].
Campos Campos F; Romero Navarro MA; Gutiérrez Samperio C; Esquivel P; Gaviño Chapa JF
Rev Gastroenterol Mex; 1989; 54(4):193-8. PubMed ID: 2616981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
